

Bictegravir 10-day Dose-Ranging Monotherapy
GS-US-141-1219

Bictegravir 10-day Dose-Ranging Monotherapy GS-US-141-1219: Design

GS-US-141-1219: Study Design

- **Background:** Randomized, double-blind, dose-ranging, placebo-controlled, 10-day, phase 1b study to evaluate antiviral activity, safety, and pharmacokinetics of the INSTI bictegravir
- **Inclusion Criteria (n = 20)**
 - Antiretroviral-naïve or
 - Antiretroviral-experienced but INSTI-naïve
 - Age: between 18 and 65
 - CD4 >200 cells/mm³
 - HIV RNA between 10,000 and 400,000 copies/mL
- **Treatment Arms**
 - Bictegravir: 5, 25, 50, or 100 mg daily
 - Placebo: daily

Bictegravir: 5 mg QD

(n = 4)

Bictegravir: 25 mg QD

(n = 4)

Bictegravir: 50 mg QD

(n = 4)

Bictegravir: 100 mg QD


(n = 4)

Placebo

(n = 4)

Bictegravir 10-day Dose-Ranging Monotherapy GS-US-141-1219: Results

Baseline to Day 11: Change in Baseline HIV RNA Level



Bictegravir 10-day Dose-Ranging Monotherapy GS-US-141-1219: Conclusions

Interpretation: “Bictegravir is a novel, potent, unboosted integrase strand transfer inhibitor (INSTI) that demonstrated rapid, dose-dependent declines in HIV-1 RNA after 10 days of monotherapy. Bictegravir was well tolerated, and displayed rapid absorption and a half-life supportive of once-daily therapy in HIV-infected subjects.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.

